Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1998:49 Suppl 2:78-81.
doi: 10.1159/000053092.

Safety of high doses of recombinant human growth hormone

K Van Loon  1
Affiliations
Review

Safety of high doses of recombinant human growth hormone

K Van Loon. Horm Res. 1998.

Abstract

Recombinant human growth hormone (r-hGH) is given as substitution therapy to growth hormone-deficient children at 0.01-0.025 mg/kg/day. Higher doses are used for short stature due to Turner's syndrome and for idiopathic short stature (approximately 0.05 mg/kg/day). For metabolic indications such as AIDS-associated wasting and severe burns, even higher doses are required, up to 0.2 mg/kg/day. Worldwide experience with low and medium doses of r-hGH is well documented. Data on long-term treatment with pharmacological doses of r-hGH are scarce. Serono's clinical program for AIDS-associated wasting provides placebo-controlled data on 355 treated patients. The total experience in clinical trials covers more than 100 person-years of treatment on approximately 600 patients. The most common side effects were tissue turgor complex and musculoskeletal discomfort. Leukopenia was found more frequently in placebo patients. Neoplasm, hyperglycemia, hypertriglyceridemia, carpal tunnel syndrome, pseudotumor cerebri and hypercalcemia were not found to be more significant than with substitution therapy.

PubMed Disclaimer

Similar articles

See all similar articles

MeSH terms

LinkOut - more resources